Business Context and Reporting Period
Company: China Pharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2025
Reporting Period: Event-based disclosure regarding a corporate action.
Business Context: The Company, incorporated in Nevada with principal offices in Haikou, Hainan Province, China, announced a significant capital structure adjustment via a press release furnished as Exhibit 99.1.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes
The primary material change disclosed is the implementation of a 1-for-10 reverse stock split.
- Effective Date: Tuesday, April 15, 2025.
- Mechanism: Every 10 shares of pre-split common stock (par value $0.001) will be converted into one post-split common share (par value $0.001).
- Trading Impact: Trading will commence on a split-adjusted basis at the market open on the effective date.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release to inform shareholders of the reverse stock split. No specific financial guidance or operational outlook was provided in this filing.
Risks and Contingencies: The filing notes that the information disclosed under Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into Securities Act filings, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the exact timing of the 1-for-10 reverse stock split effective April 15, 2025.
- Confirm the adjusted share count and par value post-split.
- Review the full text of the press release (Exhibit 99.1) for any additional details on the rationale for the split.
- Monitor trading activity on the NYSE American (Symbol: CPHI) starting April 15, 2025, for split-adjusted pricing.